{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-21-026193","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.101084+00:00","generated_at":"2026-06-28T09:40:45.204063+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Integrated BioPharma Q1 revenue down 16% to $12.8M; net income falls to $0.5M","bullets":["Revenue $12.8M vs $15.2M YoY, a decrease of 16.0%.","Operating income $0.6M vs $1.5M; net income $0.5M ($0.02 basic EPS) vs $1.0M ($0.04 basic EPS).","Diluted EPS $0.02 vs $0.03 in the prior-year quarter.","Two largest customers in Contract Manufacturing Segment accounted for ~91% of revenue, consistent with YoY.","Co-CEOs cite pandemic-related safety stock and consumer demand in prior year as cause for revenue decline."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-21-026193","json":"https://secwatch.observer/filing/0001437749-21-026193.json","markdown":"https://secwatch.observer/filing/0001437749-21-026193.md","text":"https://secwatch.observer/filing/0001437749-21-026193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774921026193/0001437749-21-026193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774921026193/inbp20211109_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:40:45.204063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}